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Abstract
Background/Aims
Limited treatment options are available for patients with hepatocellular carcinoma (HCC)
with portal vein thrombosis (PVT). Transarterial radioembolization using Yttrium-90 micro-
spheres is a new treatment modality for HCC with PVT. For this analysis, we compared
responses to treatment with radioembolization and with sorafenib.
Methods
We evaluated 32 patients who were part of a multicenter retrospective cohort. All patients
had PVT without extrahepatic metastasis and were treated with radioembolization in one of
six tertiary referral hospitals in Korea. We retrospectively enrolled another 31 consecutive
PVT patients without extrahepatic metastasis from a single center who received sorafenib
treatment to serve as the control group. We used inverse probability weighting (IPW) using
propensity scores to adjust for the between-group differences in baseline characteristics.
Results
At 3 months, the response rate and disease control rate were 32.1% (9/32) and 57.1% (16/
32), respectively, in the radioembolization group and 3.2% (1/31) and 41.9% (13/31) in the
sorafenib group. Median overall survival (OS) and time to progression (TTP) were not signif-
icantly different between the radioembolization group and the sorafenib group (13.8 months
and 10.0 months, P = 0.22; and 6.0 months and 6.0 months, P = 0.08; respectively). No
differences in OS (P = 0.97) or TTP (P = 0.34) were observed after IPW was applied to
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balance the population characteristics. The sorafenib group showed significantly more
grade 3/4 adverse effects than the radioembolization group (P < 0.01).
Conclusion
HCC patients with PVT who underwent radioembolization achieved comparable survival
to patients who received sorafenib, even after application of IPW. The radioembolization
group also experienced fewer severe adverse effects. Radioembolization can be consid-
ered a new treatment option for patients with HCC with PVT.
Introduction
In 2008, hepatocellular carcinoma (HCC) was the sixth most common cancer and the third
most frequent cause of death worldwide [1]. Patients with vascular invasion account for a large
proportion of HCC cases; these patients are classified as having advanced stage HCC, accord-
ing to the Barcelona Clinic Liver Cancer (BCLC) staging system. Portal vein thrombosis (PVT)
is the main cause of vascular invasion in HCC patients and negatively affects prognosis [2].
Definitive treatment such as liver transplantation (LT) is contraindicated in HCC patients with
PVT because patients with PVT have high recurrence rates and low cure rates. Also, PVT at
the time of LT is associated with high mortality and graft failure [3]. The BCLC classification
and western guidelines [4, 5] recommend sorafenib as the treatment of choice for HCC with
PVT on the basis of large phase III trials. However, sorafenib has low disease control rates and
offers only minor gains in overall survival (OS) [6, 7]. Neither the Sorafenib Hepatocellular
Carcinoma Assessment Randomized Protocol (SHARP) trial [8] nor the Asia-Pacific trial [9]
reported any cases of complete remission (CR) and reported only minor partial remission (PR)
after treatment with sorafenib. Those trials provide evidence to support sorafenib use for HCC
patients with PVT, but the low response rates are unsatisfactory for most clinicians.
HCC patients with PVT require novel treatments, and, since the cause of death for most
patients with advanced HCC is intrahepatic progression rather than complication from meta-
static disease, locoregional treatments such as transarterial chemoembolization (TACE) or
hepatic resection have been widely performed in Asian countries [10]. Several retrospective
studies of hepatic resection performed in HCC patients with PVT showed long term survival
[11–13]. Surgical resection is the only treatment that can achieve cure in this population, and it
has potential benefits such as decreased portal pressure and improved quality of life. Still, PVT
of the main portal vein showed a dismal prognosis in the previous studies, and patients must
be carefully selected for surgical resection. TACE is not recommended by western guidelines,
but clinicians widely use TACE for treatment of PVT; TACE is included in the consensus rec-
ommendations of the Asia-Pacific Association for the Study of the Liver [14]. A prospective
non-randomized study showed that TACE increased median survival compared to conserva-
tive treatment [15], and recent retrospective studies showed that TACE achieved comparable
outcomes to sorafenib [16]. However, TACE poses a risk of embolic side effects such as ische-
mic hepatic injuries, and treatment with TACE is contraindicated for most patients with main
PVT.
Transarterial radioembolization using Yttrium-90 (Y90) is one of the most promising tools
for treating HCC with PVT. Radioembolization delivers Y90-loaded microspheres into tumor-
feeding arteries using similar vascular access techniques as those used in TACE. The injected
microspheres emit limited radiation (mean range from the microsphere, 2.5 mm) and kill the
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tumor cells. Compared to sorafenib, radioembolization has a higher chance of CR, and, in
some cases, successful down-staging with radioembolization can lead to curative treatments
[17]. Further, radioembolization has a more tolerable side effect profile than sorafenib [18, 19].
Radioembolization also demonstrates longer time to progression (TTP) and lower rates of tox-
icity than TACE [20]. Radioembolization has similar OS in intermediate stage HCC compared
to sorafenib [21]. The theoretical advantage of performing radioembolization instead of TACE
in HCC with PVT is that radioembolization has a lower risk of ischemic side effects due to
minimal arterial occlusion [22].
Few studies have investigated the survival profiles of radioembolization in HCC with PVT
[23–25], a recent study compared radioembolization and sorafenib for intermediate to locally
advanced HCC and concluded that radioembolization and sorafenib might have comparable
outcomes [19], and another recent study compared radioembolization and sorafenib with PVT
and concluded that radioembolization has favorable outcome compared to sorafenib [26].
However, more evidences are needed for comparison of radioembolization and sorafenib in
the treatment of HCC with PVT. The aim of this study was to evaluate treatment outcomes of
radioembolization in patients with HCC with PVT and to compare the outcomes with sorafe-
nib treatment.
Materials and Methods
Patient selection
We selected patients with BCLC stage C HCC with PVT from a multicenter retrospective
cohort to investigate the effect of radioembolization in patients with intermediate or advanced
HCC. Patients underwent radioembolization from January 2008 to December 2013. We retro-
spectively enrolled consecutive HCC patients with PVT treated with sorafenib during the same
period at a single center. The study protocol conformed to the ethical guidelines of the World
Medical Association Declaration of Helsinki and was approved by the Institutional Review
Board (IRB) of Seoul National University Hospital, and also approved by the IRB of all the
other centers (Korea University, Sungkyunkwan University, The Catholic University of Korea,
Yonsei University, Pusan National University), and informed consent was waived. Patient
information was anonymized and de-identified prior to analysis. There was a previous Korean
prospective study evaluating the efficacy of radioembolization [27], the retrospective cohort of
our study was not based on the previous prospective study, but due to the retrospective nature
of the cohort there may be some overlap in the study population.
The inclusion criteria were: (a) HCC patients with PVT, (b) age of at least 18 years; (c) East-
ern Cooperative Oncology Group performance status less than or equal to 1; (d) Child-Pugh
score of A or B; (e) serum creatinine less than or equal to 1.5 mg/dL; and (f) patients undergo-
ing at least 2 weeks of sorafenib treatment. The exclusion criteria were: (a) HCC patients with
extrahepatic metastasis; (b) previous history of systemic chemotherapy; (c) LT prior to radio-
embolization; (d) and benign PVT confirmed by experienced radiologists.
A total of 154 patients were treated with radioembolization, and, of these, 47 patients had
PVT andmet the inclusion criteria. Among these, 32 patients did not have extrahepatic metasta-
sis and were selected for the radioembolization group. A total of 505 sorafenib-treated patients
were reviewed and 31 patients met the inclusion criteria and were selected for the control group
(Fig 1).
Pre-radioembolization evaluation
Subjects underwent a pre-radioembolization evaluation to evaluate the suitability to undergo
radioembolization. Firstly, diagnostic angiography was performed, the aim of the angiography
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was to assess vascular structures and to evaluate whether there is shunt from liver to other
organs. Simultaneously, technetium albumin aggregated scan (MAA) was performed, the aim
of the MAA scan was to assess the percentage of lung shunt and to predict the probability of
lung complication caused by radioembolization treatment.
Radioembolization with Y90
A repeat assessment of treatment eligibility was performed within 4 weeks before radioemboli-
zation. The volumes of tumor and normal liver were measured. The radiation dose to the
tumor was established on the basis of the manufactures protocol, but the treatment dose was
determined by each treatment team. Radiation dose outside of the tumor was calculated, and
the radiation were not allowed above the maximum dose proposed by the protocol. The deci-
sion of treatment, and whether to treat sequentially or by one-step was made by each treatment
Fig 1. Patient selection.
doi:10.1371/journal.pone.0154986.g001
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team. At the treatment period, only resin-based SIR-Spheres microspheres were available in
Korea (SirTex Medical Limited, Lane Cove, Australia).
Sorafenib treatment
Patients in the sorafenib group received a starting dose of sorafenib 400 mg twice daily. In
cases of severe adverse events, sorafenib doses were adjusted by each treating physician. Treat-
ments were continued until tumor progression or intolerable toxicity.
Clinical follow-up and response
In the radioembolization group, dynamic computed tomography was obtained for each patient
at 1 and 3 months after radioembolization and then every 3 months. In the sorafenib group,
tumor response was assessed in each patient, first after 1 or 2 months, according to the decision
of each physician, and then every 3 months. Tumor response and disease progression were
evaluated using the modified RECIST criteria. The response evaluation was based on arterial
enhancement. HCC showing no arterial enhance was defined as CR; cases with the sum of tar-
get lesions reduced by at least 30% were defined as PR. When there were new lesions, or the
sum of target lesions increased by at least 20% the response were defined as progressive disease
(PD), and all others were defined as stable disease (SD). The sum of CR and PR was defined as
the response rate, and the sum of response rate and SD was defined as the disease control rate.
Adverse effects were graded according to Common Terminology Criteria for Adverse Events,
version 4.03.
Statistical analysis
Student’s t-test was used to compare pairs of independent continuous variables. The chi-square
test or Fisher’s exact test were used to compare variables. Overall survival (OS) and time to pro-
gression (TTP) were calculated from the treatment date and death or the final observation date
in case of censoring. Univariate analysis was performed using the Cox regressing, and after-
wards multivariate Cox regression was performed to estimate the relation of prognostic factors
and survival.
To minimize selection bias, we used inverse probability weighting (IPW). Propensity scores
were calculated using generalized boosted regression to predict the probability of each patient
receiving radioembolization or sorafenib, using 10 pretreatment variables, including age, sex,
Child-Pugh score, MELD, existence of ascites, previous treatment, degree of PVT, alpha-feto-
protein, platelet, and ALT. After propensity scores were calculated, radioembolization and sor-
afenib groups were balanced by means of IPW [28].
All statistical analysis were performed using SPSS software (SPSS version 20.0; SPSS, Chi-
cago, Ill) and R Statistical Software 3.1 (R Foundation for Statistical Computing, Vienna, Aus-
tria). A two-sided P value<0.05 was considered statistically significant.
Results
Baseline characteristics of both patients are shown in Table 1. There were no significant differ-
ences in age, gender, Child-Pugh class, or prior treatment of HCC. There were significantly
more patients with main PVT in the sorafenib group than in the radioembolization group, and
the Model for End-stage Liver Disease score was worse in the sorafenib group. After we applied
IPW, the baseline characteristics were balanced and both groups did not differ significantly
(shown in S1 Table).
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Treatment responses
The characteristics of radioembolization treatments are summarized in Table 2. Responses to
radioembolization and sorafenib treatments are summarized in Table 3. In the radioemboliza-
tion group, 2 (6.3%), 7 (21.9%), and 7 (21.9%) patients showed CR, PR, and SD, respectively, at
3 months. The response rate was 28.2% (9/32) and the disease control rate was 50.1% (16/32).
At 6 months, the response rate was 6.3% (2/32) and the disease control rate was 34.4% (11/32).
In the sorafenib group, 0, 1 (3.2%), and 12 (38.7%) patients showed CR, PR, and SD, respec-
tively, at 3 months. The response rate was 3.2% (1/31) and the disease control rate was
41.9% (13/31). At 6 months, the response rate was 3.2% (1/31) and the disease control rate was
Table 1. Baseline characteristics of patients with portal vein thrombosis and without extrahepatic metastasis.
Radioembolization (n = 32) Sorafenib (n = 31) P Value
Age (years), Mean ± SD 63.7 ± 11.1 60.3 ± 10.4 0.22
Gender 0.10
Male, n (%) 26 (81.3) 30 (96.8)
Female, n (%) 6 (18.7) 1 (3.2)
Etiology
HBV, n (%) * 23 (71.9) 30 (96.8) 0.01
HCV, n (%) 5 (15.6) 0 0.05
Alcoholism, n (%) 2 (6.3) 1 (3.2) 1.00
Cryptogenic, n (%) 3 (9.4) 0 0.24
Child-Pugh score, n (%) 0.13
A 28 (87.5) 22 (71.0)
B 4 (12.5) 9 (29.0)
Ascites, n (%) 5 (15.6) 6 (19.4) 0.75
Prior treatment of HCC, n (%) 0.13
Treatment 10 (31.3) 4 (12.9)
None 22 (68.7) 27 (87.1)
Portal vein invasion, n (%) ** <0.01
Second-order 12 (37.5) 6 (19.4)
First-order 20 (62.5) 10 (32.3)
Main 0 15 (48.3)
Hepatic vein invasion, n (%) 4 (12.5) 4 (12.9) 0.63
Tumor morphology, n (%) 0.67
Uninodular and extension  50% 9 (29.0) 6 (19.4)
Multinodular and extension  50% 15 (48.4) 17 (54.8)
Massive or extension > 50% 7 (22.6) 8 (25.8)
AFP (ng/mL), n (%) 0.82
 20 ng/mL 5 (15.6) 6 (19.4)
20–200 ng/mL 7 (21.9) 5 (16.1)
>200 ng/mL 20 (62.5) 20 (64.5)
Platelet (103/mL), Mean ± SD 168.4 ± 87.9 156.2 ± 81.2 0.59
ALT (IU/L), Mean ± SD ** 49.1 ± 49.2 94.7 ± 132.9 <0.01
MELD, Mean ± SD ** 5.10 ± 3.62 7.50 ± 2.86 <0.01
SD, stand deviation; MELD, The Model for End-Stage Liver Disease; AFP, Alpha-fetoprotein
* P values < 0.05,
** P values < 0.01
doi:10.1371/journal.pone.0154986.t001
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19.4% (6/32). Compared to the sorafenib group, the radioembolization group showed a supe-
rior response rate at 3 months (P = 0.01).
Overall survival and time to progression
During follow-up, 12 patients died in the radioembolization group and 12 patients died in the
sorafenib group. The median OS and TTP of the radioembolization group and the sorafenib
group were not significantly different (13.8 months and 10.0 months, P = 0.23; and 6.0
months and 6.0 months, P = 0.08), respectively (Fig 2). No differences in OS (P = 0.97) or TTP
(P = 0.34) were observed (Fig 3), even after we applied IPW. The baseline characteristics of the
balanced population are shown in the supplemental material (S1 Table).
In the univariate analysis, the OS was significantly associated with the Child-Pugh score and
tumor morphology (Table 4). We used these variables in a multivariate Cox analysis, which
revealed that a high Child-Pugh score (hazard ratio [HR], 2.75; 95% confidence interval [CI],
1.04–7.29; P = 0.04) and massive tumor morphology (HR, 5.01; 95% CI, 1.00–25.1; P = 0.05)
were associated with worse survival.
Toxicity
Among the radioembolization group, the most common adverse effects were nausea or vomit-
ing (21.9%) and abdominal pain (18.8%). In the sorafenib group, the most common adverse
Table 2. Radioembolization treatment characteristics.
All patients (n = 32)
Target Treatment, n (%)
Whole liver 4 (12.5)
Right lobe 10 (31.3)
Left lobe 4 (12.5)
Segmental 11 (34.4)
Missing 3 (9.3)
Target tumor volume (ml), mean (range) 511.9 (5.0–1754.9)
Target liver volume (ml), mean (range) 1046.6 (280.0–1845.0)
Whole liver volume (ml), mean (range) 1701.9 (998.3–2522.6)
Total injected activity (GBq), mean (range) 2.08 (0.28–4.93)
Lung shunt (%), mean (range) 9.76 (1.63–35.4)
doi:10.1371/journal.pone.0154986.t002
Table 3. Response to treatment.
3 months 6 months
Radioembolization (n = 32) Sorafenib (n = 31) P Value Radioembolization (n = 32) Sorafenib (n = 31) P Value
CR, n (%) 2 (6.3) 0 0.49 2 (6.3) 0 0.54
PR, n (%) 7 (21.9) 1 (3.2) 0.05 0 1 (3.2) 0.33
SD, n (%) 7 (21.9) 12 (38.7) 0.10 9 (28.1) 5 (16.1) 1.00
PD, n (%) 12 (37.5) 13 (41.9) 0.59 9 (28.1) 4 (12.9) 1.00
Overall, n (%) 28 (87.5) 26 (83.9) 20 (62.5) 10 (32.3)
Response rate, n (%) 9 (28.1) 1 (3.2) 0.01* 2 (6.3) 1 (3.2) 1.00
Disease control rate, n (%) 16 (50.0) 13 (41.9) 0.78 11 (34.4) 6 (19.4) 1.00
CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease
* P values < 0.05
doi:10.1371/journal.pone.0154986.t003
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Fig 2. Survival analysis. (A) Overall survival and (B) Time to progression of patients treated with sorafenib and radioembolization.
doi:10.1371/journal.pone.0154986.g002
Fig 3. Survival analysis of balanced population after inverse probability weighting. (A) Overall survival and (B) Time to progression of patients
treated with sorafenib and radioembolization.
doi:10.1371/journal.pone.0154986.g003
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effect was diarrhea (13.0%). There were significantly more severe adverse events (grade 3/4) in
the sorafenib group than in the radioembolization group (5/31 and 1/32; P< 0.01, respectively;
Table 5).
Discussion
Radioembolization is emerging as a valuable treatment option for PVT. The results of this
study indicate that comparable response rates can be achieved with radioembolization and
Table 4. Univariate andmultivariate cox-regression of patients included.
Overall Survival—univariate Overall Survival—multivariate
Parameter HR (95% CI) P Value HR (95% CI) P Value
Age 0.97 (0.93–1.02) 0.17
Sex
Female 1.24 (0.37–4.23) 0.73
Treatment
Sorafenib treatment 1.63 (0.73–3.66) 0.23
Child-Pugh score
A 1 1
B 2.41 (1.03–5.63) 0.04 * 2.75 (1.04–7.29) 0.04 *
Ascites present 1.78 (0.66–4.87) 0.25
Prior treatment of HCC
Treatment 1.13 (0.50–2.53) 0.77
Portal vein invasion
Second-order 1
First-order 0.76 (0.32–1.85) 0.55
Main 0.80 (0.25–2.58) 0.71
Tumor morphology, n (%)
Uninodular and extension  50% 1 1
Multinodular and extension  50% 3.57 (0.80–15.8) 0.09 4.23 (0.94–19.6) 0.06
Massive or extension > 50% 5.70 (1.16–28.0) 0.03 * 5.01 (1.00–25.1) 0.05 *
MELD 1.08 (0.97–1.20) 0.16
HCC, hepatocellular carcinoma; MELD, The Model for End-Stage Liver Disease
* P values < 0.05,
** P values < 0.01
doi:10.1371/journal.pone.0154986.t004
Table 5. Adverse effects according to CTCAE ver 4.03.
Radioembolization Sorafenib
Grade 1/2 Grade 3/4 Grade 1/2 Grade 3/4 P value
Nausea or vomiting, n (%) 7 (21.9) 0 1 (3.2) 1 (3.2) 0.14
Anorexia, n (%) 0 0 1 (3.2) 0 0.07
Diarrhea, n (%) 0 0 2 (6.5) 2 (6.5) <0.01
Abdominal pain, n (%) 6 (18.8) 0 1 (3.2) 1 (3.2) 0.03
Fever, n (%) 0 0 0 0 -
Weight loss, n (%) 0 0 0 0 -
Bleeding, n (%) 0 0 0 1 (3.2) <0.01
Splenic infarction, n (%) 0 1 (3.1) 0 0 <0.01
doi:10.1371/journal.pone.0154986.t005
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with sorafenib. The median survivals of the radioembolization group (13.8 months) and the
sorafenib group (10.0 months) were not significantly different, and CR cases (6.3%) only
occurred in the radioembolization group. We applied IPW to overcome imbalances in baseline
characteristics, and, after establishing a balanced population, the two treatment groups still
showed no significant differences in survival or progression. In fact, the sorafenib group
showed significantly more grade 3/4 adverse events than the radioembolization group. The
results of our study support the use of radioembolization to treat HCC patients with PVT.
The median survivals reported in our study are comparable with previous studies. Few stud-
ies have reported that radioembolization can be delivered with positive outcomes in HCC
patients with PVT, and those studies reported median OS ranging from 5.6 to 13.8 months [17,
23–26]. The extent of PVT and Child-Pugh classification are the main prognostic factors that
affect survival in HCC. A previous study showed that patients with branch PVT had a better
prognosis than patients with main PVT (10.7 vs 9.7 months, respectively) [29], and another
study showed that patients with Child-Pugh A disease had a better prognosis than patients
with Child-Pugh B7 disease (13.8 vs 6.5 months, respectively). Sub-analyses of the SHARP
study and the Asian-Pacific trial revealed that patients with macrovascular vessel invasion had
median OS of 8.1 [6] and 5.6 [7] months, respectively. We observed median OS of 10.0 months
in the sorafenib group and 13.8 months in the radioembolization group. These findings can be
partly explained by the exclusion of HCC patients with extrahepatic metastasis, which is
known to be associated with poor prognosis [30]. A recent study comparing radioembolization
and sorafenib for intermediate to locally advanced HCC showed median OS of 14.4 months in
the sorafenib group and 13.2 months in the radioembolization group [19], which are compara-
ble to the findings of our study. Another study comparing radioembolization and sorafenib for
HCC with PVT showed median OS of 8.8 months in the radioembolization group and 6.7
months in the sorafenib group [26], which showed shorter OS compared to our study, but this
study included patients with extrahepatic metastasis. Therefore, the existence of extrahepatic
metastasis might influenced the OS negatively in this study. Although western guidelines sug-
gest sorafenib as the treatment of choice for HCC patients with PVT [4, 5], the survival gain of
sorafenib compared to placebo is minimal, especially in subgroup analyses of vascular invasion.
Further, the SHARP trial and the Asian-Pacific trial reported no CR cases. Because of the need
for effective treatment options for HCC with PVT, locoregional treatments are frequently per-
formed in real world practice, especially in Asian countries, which is reflected in the Asia-
Pacific guidelines [14]. PVT in HCC is associated with both intrahepatic and extrahepatic
spread, and using sorafenib to treat PVT as a systemic disease has recognized rationale, and
large randomized controlled studies have proved survival gains from this treatment. However,
without effective local control, sorafenib is unlikely to control this life-threatening condition
effectively, and local control of PVT should be attempted if it is possible and patients are eligi-
ble [31]. Patients with locally advanced HCC with no extrahepatic metastasis and vascular
invasion only have favorable outcomes compared to patients with HCC with extrahepatic
metastasis [30]. This may suggest that, in this specific patient population, PVT can be treated
in a locoregional manner. Treating PVT with a locoregional method is less invasive, allows
down-staging that can permit LT, and, in certain cases, shows dramatic outcomes compared to
sorafenib [31]. The main problem with the use of TACE to treat patients with PVT is that
embolization of PVT can cause acute decompensation. Compared to TACE, radioembolization
shows better arterial patency and less embolization. For this reason, radioembolization is
believed to have a lower risk of post-embolization syndrome and a better safety profile than
sorafenib [22]. Accordingly, in our study, the radioembolization group showed significantly
less severe adverse events, and no cases of acute hepatic decompensation occurred in either the
radioembolization group or the sorafenib group.
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Radioembolization might be an important tool in the treatment of HCC patients with PVT.
Two randomized control studies are currently ongoing to clarify this issue: the SARAH study
(Sorafenib versus Radioembolization in Advanced Hepatocellular carcinoma, ClinicalTrials.
gov identifier NCT01482442) and the STOP HCC study (Efficacy Evaluation of TheraSphere
in Patients With Inoperable Liver Cancer, ClinicalTrials.gov identifier NCT01556490). As pre-
viously mentioned, a recent Italian study found that radioembolization and sorafenib showed
comparable outcomes for intermediate to locally advanced HCC [19], and a previous Spanish
study found that radioembolization showed superior outcomes for HCC with PVT [26].
The strength of our study compared to previous studies is that we focused on patients with
locally advanced HCC with PVT. Therefore, the results of this study offer direct evidence to
support treating HCC patients with PVT with radioembolization. Although a recent study
compared radioembolization in HCC patients with PVT, the results of our study provides valu-
able data in the debatable issue. Since this study was performed in an Asian population, it also
provides validation for radioembolization in a setting where hepatitis B is the predominant
cause of liver cirrhosis.
There are several limitations of our study. First, the study is performed with retrospective
design. In order to overcome this weakness, we performed IPW and matched the characteris-
tics of the sorafenib and the radioembolization groups. Second, the study population was rela-
tively small to reach definitive conclusions and additional stratification based on important
clinical variables such as extent of PVT could not be performed. Ongoing or future clinical tri-
als with a sufficient number of patients would allow definitive conclusions to be drawn. Third,
although we excluded benign PVTs confirmed by experienced radiologists, some PVTs we
treated as tumor invasion may be potentially benign PVTs. Fourth, most radioembolization
treated patients followed up at fixed intervals, but sorafenib patients followed up at intervals
depending to each physician’s decision. This may make bias at TTP analysis, but the primary
endpoint was overall survival, and this bias is not critical in this study.
Radioembolization showed comparable response rates to sorafenib in HCC patients with
PVT. We suggest that radioembolization should be considered a new treatment option in this
population. Results of ongoing, randomized, controlled studies on this subject will yield further
evidence of our findings. To date, radioembolization has been an important option for HCC
patients with PVT, and further studies are needed to define which subgroups will benefit from
radioembolization or sorafenib.
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